Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: A Cohort study

BMJ Open

Volumn 3, Issue 1, 2013, Pages

  Martinez, Carlos ^a   Jones, Roy W ^b   Rietbrock, Stephan ^a  

^a Independent Pharmacoepidemiologist   (Germany)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPNOTIC AGENT; MEMANTINE; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; DEMENTIA; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; TREATMENT DURATION; UNITED KINGDOM;

EID: 84873466648     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002080     Document Type: Article

References (39)

1. Georges J, Jansen S, Jackson J, et al. Alzheimer's disease in real life-the dementia carer's survey. Int J Geriatr Psychiatry 2008;23:546-51. (Pubitemid 351722116)
2. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008;23:170-7. (Pubitemid 351308497)
3. Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-51. (Pubitemid 20257519)
4. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090-7. (Pubitemid 34437344)
5. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38. (Pubitemid 44547805)
6. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
7. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009;8:151-7.
8. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. (Pubitemid 41464695)
9. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. (Pubitemid 41713745)
10. MHRA. Antipsychotics: use in elderly people with dementia. Drug Saf Update 2009;1:5.
11. U. S. Food and Drug Administration. Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioural disturbances (Internet). 11 April 2005. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM053171 (accessed 2 Aug. 2012).
12. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. An independent report commissioned and funded by the UK Department of Health. 2009. http://www.dh.gov. uk/prod-consum-dh/groups/dh- digitalassets/documents/digitalasset/dh-108302.pdf (accessed 9 Aug. 2012).
13. Desplanques-Leperre A, Riolacci N, Blin, et al. Understanding and improving the prescription of psychotropic drugs in the elderly in France. Presented at the International Forum on Quality and Safety in Health Care (IFQSHC) (Internet). Presented 19 March 2009. http://www.has-sante.fr/portail/ upload/docs/application/pdf/2009-03/abstract-has-ifqshc-march2009.pdf (accessed 2 Jul. 2012).
14. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009;5:245-55.
15. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-8. (Pubitemid 351549385)
16. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-45. (Pubitemid 351722115)
17. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-16. (Pubitemid 36068709)
18. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19. (Pubitemid 38971117)
19. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1387-92.
20. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology 2008;31:193-200.
21. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011;68:190-7.
22. Erratum in: Arch Gen Psychiatry. 2011 May; 68:466. Ignacio, Rosalindo (corrected to Ignacio, Rosalinda V). PubMed PMID: 21300946.
23. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004;27:871-81. (Pubitemid 39331685)
24. Read Codes-NHS Connecting for Health. http://www.connectingforhealth.nhs. uk/systemsandservices/data/uktc/readcodes (accessed 2 Nov. 2012).
25. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309. (Pubitemid 34989269)
26. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 2002;288:1475-83.
27. Modrego PJ, Ferrández J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004;61:1290-3. (Pubitemid 39062687)
28. National Dementia and Antipsychotic Prescribing Audit 2012. Health and Social Care Information Centre. http://www.ic.nhs.uk/webfiles/Services/NCASP/ audits%20and%20reports/National-Dementia-and-Antipsychotic-Prescribing-Audit- National-Report-V1. 0-17-07-12-Interactive.pdf (accessed 8 Nov. 2012).
29. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
30. Citalopram and escitalopram: QT interval prolongation-new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Saf Update 2011;5:A1.
31. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; (2): CD008191.
32. Passmore AP, Craig DA. The future of memory clinics. Psychiatrist 2004;28:375-7. (Pubitemid 39359700)
33. NHS Workforce Review Team 2008. Workforce summary-old age psychiatry. http://www.cfwi.org.uk/intelligence/previous-projects/workforce-summaries/ old-age-psychiatry (accessed 2 Nov. 2012).
34. NICE technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. November 2006 (amended September 2007, August 2009) (amended). This guidance has been replaced by TA217 and is no longer available. http://publications. nice.org.uk/donepezil-galantamine-rivastigmine-review-andmemantinefor-the- treatment-of-alzheimers-ta111 (accessed 2 Nov. 2012).
35. NICE technology appraisal guidance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Review of NICE technology appraisal guidance 111. Issued March 2011. http://www.nice.org. uk/nicemedia/live/13419/53619/53619.pdf (accessed 8 Jun. 2011).
36. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154.
37. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's disease: a randomised double-blind placebo controlled trial. PLoS One 2012;7:e35185.
38. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903.
39. Craig D, Mirakhur A, Hart DJ, et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 2005;13:460-8.